Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144773 | 0.86 | USP2 (0.44) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 | |
| SCHEMBL1446792 | 0.84 | MEN1 (0.39) | HPGDUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL17707510 | 0.84 | USP2 (0.45) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 | |
| SCHEMBL7453562 | 0.82 | CYP4F2 (0.45) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 | |
| SCHEMBL29215638 | 0.82 | USP2 (0.43) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 | |
| SCHEMBL7303096 | 0.81 | USP2 (0.47) | HPGDUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL965651 | 0.81 | USP2 (0.51) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 | |
| SCHEMBL17608984 | 0.81 | CYP4F2 (0.44) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 | |
| SCHEMBL15740834 | 0.81 | USP2 (0.42) | HPGDUSP2SMN1; SMN2RECQLGPR119 | |
| SCHEMBL14155541 | 0.80 | USP2 (0.46) | HPGDUSP2SMN1; SMN2RECQLCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297153-B1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2015-05-27 | — | — | EP | disclosed |
| CN-101565420-B | Limk2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS INC | 2015-05-20 | — | — | CN | disclosed |
| EP-2674433-A1 | LIMK2 inhibitors, compositions comprising them and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8450332-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-12-27 | — | — | US | disclosed |
| US-8193202-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2297153-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009131940-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-101565420-A | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2009-10-28 | — | — | CN | disclosed |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | HPGD 3269/4885USP2 1948/4885SMN1; SMN2 1340/4885 |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | HPGD 3269/4885USP2 1948/4885SMN1; SMN2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.